Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | IL1B | P01584 | 2/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24266897 | 0.95 | CRBN (0.49) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL20153862 | 0.92 | CRBN (0.61) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL20153897 | 0.88 | CRBN (0.47) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL19629704 | 0.83 | CRBN (0.52) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL22873320 | 0.82 | CRBN (0.45) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL22006041 | 0.82 | TSHR (0.41) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL22873882 | 0.81 | CRBN (0.51) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL19629708 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL19629754 | 0.81 | TSHR (0.43) | TSHRALDH1A1CYP1A2 | |
| SCHEMBL21214939 | 0.79 | CRBN (0.51) | CRBNDDB1IKZF3TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9822098-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885DDB1 2485/4885IKZF3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.